Jorge J. Castillo, MD

• Waldenström's Macroglobulinemia

Dr. Castillo was born in Peru, received his medical degree at the Universidad Autonoma Metropolitana in Mexico City, and completed his Internal Medicine, and Hematology & Oncology training at the University of Massachusetts and Brown University, respectively. Dr. Castillo is an Associate Professor at Harvard Medical School, Senior Physician at the Dana-Farber Cancer Institute, and Clinical Director of the Bing Center for Waldenström Macroglobulinemia.

Dr. Castillo is the principal investigator in innovative clinical trials evaluating highly effective non-chemotherapeutic approaches for patients with Waldenström macroglobulinemia. Research grants were obtained from Abbvie and Pharmacyclics to study the combination of ibrutinib and venetoclax in previously untreated Waldenström Macroglobulinemia (DFCI 19-651), AstraZeneca to investigate the combination of acalabrutinib and rituximab in patients with anti-MAG neuropathy (DFCI 21-439), and LOXO to investigate the combination of pirtobrutinib and venetoclax in patients with previously treated Waldenström Macroglobulinemia (DFCI 22-611). Funding from the Kaplan Family and the International Waldenström Macroglobulinemia Foundation was secured to create the Waldenström Macroglobulinemia Clinical Trial Network. Additional funding was secured from the Bell Family to create a research fellowship position to focus on translational, transformative basic research at the Bing Center for Waldenström Macroglobulinemia laboratory.